Microbiome Therapy for Graft-Versus-Host Disease Faces

What Is MaaT Pharma Asking European Regulators To Reconsider?

MaaT Pharma is pursuing a European re-examination after a regulatory setback for its investigational microbiome therapy in graft-versus-host disease, according to Fierce Pharma's regulatory tracker. In the European Medicines Agency system, companies may request re-examination after a negative opinion from the Committee for Medicinal Products for Human Use, giving sponsors an opportunity to address scientific concerns before a final European Commission decision.

The medical stakes are high because acute graft-versus-host disease can occur after allogeneic hematopoietic stem cell transplantation, when donor immune cells attack the recipient's tissues. The gut, skin, and liver are commonly affected, and patients who do not respond adequately to corticosteroids have limited options and substantial risk of severe infection, organ failure, and death.

Why Are Microbiome Therapies Being Studied For GVHD?

The scientific rationale comes from years of transplant research linking intestinal microbiome injury with worse outcomes after allogeneic transplant. Broad-spectrum antibiotics, chemotherapy, mucosal injury, and immune suppression can reduce microbial diversity, and several studies have associated lower gut microbiome diversity with higher transplant-related mortality and graft-versus-host disease risk.

Microbiome-based medicines aim to restore a more resilient microbial ecosystem rather than suppress immunity directly. That makes the approach attractive in GVHD, where clinicians must balance immune control against infection risk. However, live biotherapeutic products also raise difficult regulatory questions about manufacturing consistency, donor screening, potency testing, and how best to measure clinical benefit in a fragile population.

What Treatments Are Currently Used For Steroid-Refractory GVHD?

Systemic corticosteroids are widely used as initial treatment for acute graft-versus-host disease, but not all patients respond. In the United States, the FDA has approved ruxolitinib, a JAK inhibitor, for steroid-refractory acute GVHD in adults and pediatric patients 12 years and older, based on clinical trial evidence showing improved response compared with available therapies.

Even with approved drugs, steroid-refractory GVHD remains a difficult clinical area. Patients often have competing risks from infection, relapse of the original blood cancer, organ toxicity, and prolonged immune suppression. Any new therapy must show that it improves meaningful outcomes without adding unacceptable safety risks, which helps explain why regulators scrutinize evidence closely.